Pavaki Capital Management »

Crispr Therapeutics shares owned by Pavaki Capital Management

Quarter-by-quarter ownership of Crispr Therapeutics (CRSP) shares owned by Pavaki Capital Management from 13F filings

Historical chart of Pavaki Capital Management investment in Crispr Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Crispr Therapeutics held by Pavaki Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Crispr Therapeutics by Pavaki Capital Management

Quarter filed Position value Share count Share price at filing
2026-09-30 $277k 5.0k 55.32

More positions owned by Pavaki Capital Management

Carvana Cl A Call Option (CVNA)
NVIDIA Corporation (NVDA)
Chevron Corporation (CVX)
Tesla Motors Call Option (TSLA)
Palantir Technologies Cl A Call Option (PLTR)
Intuit (INTU)
Barrick Mng Corp Com Shs (B)
Qualcomm (QCOM)
Regeneron Pharmaceuticals (REGN)
Invesco Qqq Tr Unit Ser 1 Call Option (QQQ)
Milestone Pharmaceuticals (MIST)
Textron (TXT)
B2gold Corp (BTG)
Arcutis Biotherapeutics (ARQT)
Micron Technology (MU)

View all positions for Pavaki Capital Management

Top funds holding Crispr Therapeutics

ARK Investment Management
BlackRock
Orbis Allan Gray
State Street Corporation
GSK
Geode Capital Management
Sr One Capital Management
Two Sigma Investments
FMR
Sumitomo Mitsui Trust Holdings
Nikko Asset Management Americas
EcoR1 Capital
UBS Group
Capital Research and Management Company - Division 3
Vanguard Capital Management

View all funds holding Crispr Therapeutics